Skip to main content
main-content

The independent medical news service

Lung cancer

17-04-2019 | Oncology | News | Article

Conflicting data reported on immunotherapy benefit for older NSCLC patients

The overall survival benefit of immunotherapy in elderly patients with advanced non-small-cell lung cancer is unclear according to two studies with contradictory results presented at the European Lung Cancer Congress 2019 in Geneva, Switzerland.

16-04-2019 | Oncology | News | Article

CheckMate 451: Maintenance immunotherapy fails to improve SCLC survival

Maintenance treatment with nivolumab, either given alone or alongside ipilimumab, does not prolong the overall survival of patients with extensive-stage small-cell lung cancer, the CheckMate 451 investigators have found.

12-04-2019 | Oncology | News | Article

ALK resistance mutations predict lorlatinib efficacy in NSCLC patients progressing on ALK–TKIs

Lorlatinib is more efficacious against non-small-cell lung cancer with versus without ALK resistance mutations in patients with disease progression after at least one second-generation ALK–tyrosine kinase inhibitor, suggests research.

12-04-2019 | Oncology | News | Article

KEYNOTE-042 leads to first-line pembrolizumab approval for stage III NSCLC

Read more on this FDA announcement here

12-04-2019 | Oncology | Highlight | Article

Lung cancer screening benefits increase over time

The Multicentric Italian Lung Detection study findings indicate that extending lung cancer screening beyond 5 years boosts the survival benefits associated with early disease detection.

10-04-2019 | Oncology | News | Article

Clinical value of genotyping cfDNA demonstrated in advanced NSCLC setting

The NILE study has shown the noninferiority of cell-free DNA analysis, so-called liquid biopsy, to the standard of care for identifying targetable biomarkers in individuals with treatment-naïve metastatic non-small-cell lung cancer.

09-04-2019 | Oncology | News | Article

Durvalumab maintenance for unresectable NSCLC approved for UK patients

Read more on this decision here

05-04-2019 | Oncology | News | Article

Entrectinib has antitumor efficacy in NTRK fusion-positive tumors

The multikinase inhibitor entrectinib elicits systemic and intracranial responses in patients with locally advanced or metastatic solid tumors harboring NTRK fusions, including those with non-small-cell lung cancer, suggests a pooled analysis of three early-phase clinical trials.

03-04-2019 | Oncology | Highlight | Article

Osimertinib combinations promising for NSCLC patients with acquired resistance to EGFR–TKIs

Data from the phase Ib TATTON trial suggest that patients with EGFR-mutated non-small-cell lung cancer who have progressed on prior EGFR–tyrosine kinase inhibitor therapy could benefit from adding either the MET inhibitor savolitinib or the MEK inhibitor selumetinib to osimertinib.

02-04-2019 | Oncology | News | Article

Pembrolizumab supported for third- or later-line extensive-stage SCLC

Single-agent pembrolizumab could be a promising option for extensive-stage small-cell lung cancer patients who have received at least two prior lines of therapy, suggests a pooled analysis of data from the multicohort KEYNOTE-028 and -158 trials.

02-04-2019 | Oncology | News | Article

Potential of dual checkpoint blockade shown for neuroendocrine tumors

Patients with high-grade neuroendocrine tumors may benefit from combined treatment with the PD-1 inhibitor nivolumab and the anti-CTLA-4 agent ipilimumab, indicate phase II results.

01-04-2019 | Oncology | News | Article

Mesothelin-targeted CAR T-cell therapy shows promise for malignant pleural disease

Phase I results reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, point to the potential of a chimeric antigen receptor T-cell therapy directed against mesothelin in patients with malignant pleural disease.

29-03-2019 | Oncology | News | Article

Flu vaccine not contraindicated for checkpoint inhibitor-treated cancer patients

A US chart review has found no increase in the incidence of severe immune-related adverse events among advanced cancer patients who receive an influenza vaccination during the 2 months before or after initiating immune checkpoint inhibitor therapy.

28-03-2019 | Non-small-cell lung cancer | News | Article

Gene panel guides immune checkpoint inhibitor therapy in NSCLC patients

Researchers report that a cancer gene panel called NCC-GP150 may be able to accurately estimate blood tumor mutational burden in patients with non-small-cell lung cancer, and identify those most likely to benefit from immune blockade therapy.

25-03-2019 | Oncology | Main feed | News

FDA approves atezolizumab for extensive-stage SCLC

Click here to read more on this announcement

15-03-2019 | Non-small-cell lung cancer | News | Article

Risk for severe irAEs noted with sequential PD-1/PD-L1 blockade and osimertinib

Patients with advanced EGFR mutation-positive non-small-cell lung cancer who receive osimertinib directly after agents targeting PD-1 or PD-L1 may be at increased risk for developing severe immune-related adverse events, suggests a chart review.

14-03-2019 | Oncology | News | Article

Aspirin does not improve prostate cancer-specific survival, but may reduce lung cancer incidence

A Danish study has found no protective effect of low-dose aspirin taken after diagnosis on prostate cancer-specific mortality, while South Korean research has identified a link between long-term use of the nonsteroidal anti-inflammatory drug and a reduced risk for incident lung cancer.

11-03-2019 | Non-small-cell lung cancer | News | Article

CheckMate 568 identifies ‘clinically meaningful’ TMB cutoff for advanced NSCLC

A tumor mutational burden cutoff of 10 mutations/Mb could help identify advanced non-small-cell lung cancer patients who are most likely to benefit from first-line treatment with nivolumab plus low-dose ipilimumab, report the CheckMate 568 investigators.

05-03-2019 | Non-small-cell lung cancer | News | Article

Lorlatinib given European NSCLC approval

Click here for further information

01-03-2019 | Oncology | News | Article

Sex disparity identified for hyperprogressive disease after immunotherapy

Women may be at greater risk than men for experiencing hyperprogression as a response to cancer treatment with immune checkpoint inhibitors, say researchers.

image credits